Results 211 to 220 of about 557,898 (308)
Influenza Vaccination in Spain: Understanding the Impact of Suboptimal Coverage on Health, Society, and the Economy. [PDF]
Onieva-García MÁ +4 more
europepmc +1 more source
A nanomotor featuring an “electronic lock” via electron compensation in an Au‐Ag alloy ensures therapeutic precision. Near‐infrared light acts as a key, unlocking on‐demand Ag+ release for synergistic bactericidal action and microenvironment remodeling to potently treat bacterial pneumonia. Abstract Bacterial pneumonia treatment is severely hampered by
Chenglong Xue +4 more
wiley +1 more source
Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim +9 more
wiley +1 more source
Decreases in influenza vaccination coverage among nursing home healthcare workers and in measures to promote influenza vaccination, France, 2007/08 to 2024/25. [PDF]
Hanguehard R +5 more
europepmc +1 more source
Opsoclonus in Pediatric Patients: Differential Diagnosis and a Practical Approach to Evaluation
ABSTRACT Opsoclonus is an ocular dyskinesia characterized by involuntary, arrhythmic, multidirectional saccades. In pediatrics, opsoclonus is most commonly attributed to the rare neuroinflammatory disorder opsoclonus‐myoclonus‐ataxia syndrome (OMAS), typically considered a paraneoplastic syndrome associated with neural crest tumors. However, opsoclonus
Aubrey C. Reed +5 more
wiley +1 more source
Predictors of influenza vaccination among Iranian pregnant women based on a combined Health Belief Model and Theory of Planned behavior. [PDF]
Yousefi M +5 more
europepmc +1 more source
Dengue virus (DENV) infection is a significant global health threat. Mosnodenvir (JNJ‐64281802) is a pan‐serotype small molecule antiviral blocking DENV replication. A Phase IIa study (NCT05048875) evaluated the antiviral activity, safety, and pharmacokinetics of mosnodenvir as prophylaxis against DENV‐3 in a controlled human infection model (CHIM).
Nele Goeyvaerts +8 more
wiley +1 more source
Influenza Vaccination Trends Among Children and Adolescents, 2017-2023.
Rane MS +4 more
europepmc +1 more source

